Cite
Ruppert AS, Booth AM, Ding W, et al. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021;35(10):2854-2861doi: 10.1038/s41375-021-01342-x.
Ruppert, A. S., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Coutre, S., Brown, J. R., Nattam, S., Larson, R. A., Erba, H., Litzow, M., Owen, C., Kuzma, C. S., Abramson, J. S., Little, R. F., Smith, S. E., Stone, R. M., Byrd, J. C., Mandrekar, S. J., & Woyach, J. A. (2021). Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia, 35(10), 2854-2861. https://doi.org/10.1038/s41375-021-01342-x
Ruppert, Amy S, et al. "Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202." Leukemia vol. 35,10 (2021): 2854-2861. doi: https://doi.org/10.1038/s41375-021-01342-x
Ruppert AS, Booth AM, Ding W, Bartlett NL, Brander DM, Coutre S, Brown JR, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma CS, Abramson JS, Little RF, Smith SE, Stone RM, Byrd JC, Mandrekar SJ, Woyach JA. Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia. 2021 Oct;35(10):2854-2861. doi: 10.1038/s41375-021-01342-x. Epub 2021 Jul 17. PMID: 34274940.
Copy
Download .nbib